Tech News, Tech & Coding · Free Online Tools

IT Question Answer
Tools
Back to AI
FDA seeks public input on how to regulate generative AI medical devices

FDA seeks public input on how to regulate generative AI medical devices

AIBy Muhammad FareedFDA press announcement (August 18, 2026)
fdagenerative aimedical devicesregulationdigital health

What the FDA published

On August 18, 2026, the US Food and Drug Administration issued a discussion paper on how to regulate medical devices that use generative AI and asked for public feedback. Comments were due by October 19, 2026, through docket FDA-2026-N-7874 on Regulations.gov. The paper covers risk assessment, premarket evaluation and postmarket monitoring.

Ideas in the paper

  • A two-axis risk framework for judging how risky a generative AI device is.
  • A premarket approach based on competency assessment, loosely modeled on how physicians are trained and evaluated. It would combine non-clinical benchmarking of the device with clinical confirmation.
  • Options for postmarket monitoring that match the level of risk.
  • Special considerations for foundation models and agentic AI systems.

Why generative AI devices are different

The FDA said these devices may offer significant benefits for patient care but can pose risks different from those of traditional software and earlier AI-enabled devices. A generative model can produce new text or images, may give different answers to the same input and can change as models are updated. Standard testing that works for a fixed algorithm is harder to apply.

What officials said

Acting FDA Commissioner Kyle Diamantas said artificial intelligence is transforming medicine. Michelle Tarver, director of the Center for Devices and Radiological Health, said patients and clinicians deserve a regulatory approach that keeps pace. The director of the Digital Health Center of Excellence, Rick Abramson, said generative AI-enabled devices are poised to reshape the health technology landscape.

Who should care

  • Developers of AI scribes, diagnostic assistants and patient-facing chat tools that may count as medical devices.
  • Hospitals deciding how to evaluate and monitor AI tools.
  • Patients and clinicians who rely on the accuracy of these systems.

What happens next

A discussion paper is not a rule. After reviewing comments, the FDA may issue draft guidance, which would also go through public comment before it is final. The sources reviewed did not give a timeline.

For a recent drug approval, see our report on dostarlimab for rectal cancer.

Advertisement